How I treat transfusional iron overload by A.V. Hoffbrand et al.
doi:10.1182/blood-2012-05-370098
Prepublished online August 23, 2012;
2012 120: 3657-3669
 
 
 
 
A. Victor Hoffbrand, Ali Taher and Maria Domenica Cappellini
 
How I treat transfusional iron overload
 http://bloodjournal.hematologylibrary.org/content/120/18/3657.full.html
Updated information and services can be found at:
 (406 articles)Red Cells, Iron, and Erythropoiesis   
 (107 articles)How I Treat   
 (1569 articles)Free Research Articles   
Articles on similar topics can be found in the following Blood collections
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
 http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
 http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
 Copyright 2011 by The American Society of Hematology; all rights reserved.
Washington DC 20036.
by the American Society of Hematology, 2021 L St, NW, Suite 900, 
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly
 
 
 
 
 use only.
For personal at BIBLIOTECA POLO SAN PAOLO on January 11, 2013. bloodjournal.hematologylibrary.orgFrom 
How I treat
How I treat transfusional iron overload
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Patients with -thalassemia major (TM)
and other refractory anemias requiring
regular blood transfusions accumulate
iron that damages the liver, endocrine
system, and most importantly the heart.
The prognosis in TM has improved re-
markably over the past 10 years. This
improvement has resulted from the devel-
opment of magnetic resonance imaging
(MRI) techniques, especially T2*, to accu-
rately measure cardiac and liver iron, and
from the availability of 3 iron-chelating
drugs. In this article we describe the use
of MRI to determine which adult and pedi-
atric patients need to begin iron chelation
therapy and to monitor their progress. We
summarize the properties of each of the
3 drugs, deferoxamine (DFO), deferiprone
(DFP), and deferasirox (DFX), including
their efficacy, patient acceptability, and
side effects. We describe when to initiate
or intensify therapy, switch to another
drug, or use combined therapy. We also
discuss the management of refractory
anemias other than TM that may require
multiple blood transfusions, including
sickle cell anemia and myelodysplasia.
The development of a potential fourth
chelator FBS 0701 and the combined use
of oral chelators may further improve the
quality of life and survival in patients with
TM and other transfusion-dependent pa-
tients. (Blood. 2012;120(18):3657-3669)
Introduction
Iron overload is a major concern in patients with congenital and
acquired anemias for whom regular transfusions are needed
(Table 1). Under normal conditions, iron absorption and loss are
balanced at  1 mg/day. Transfused blood contains 200-250 mg
of iron per unit. Hence, patients with -thalassemia major (TM)
or other refractory anemias receiving 2-4 units of blood per
month have an annual intake of 5000-10 000 mg of iron or
0.3-0.6 mg/kg per day. The body has no mechanism for excret-
ing this excess iron. Moreover, patients with TM and other
anemias characterized by ineffective erythropoiesis absorb
excess iron despite iron overload because of production of
GDF15 and possibly other proteins (eg, TWSGI) from erythro-
blasts, which inhibit hepcidin synthesis.1
Untreated transfusional iron load results in damage to the liver,
endocrine organs, and most importantly to the heart. In TM,
without effective iron chelation, death occurs from cardiac failure
or arrhythmia, usually in late childhood or in the teenage years.
Most studies of iron chelation therapy have been carried out in TM
for which all patients need transfusions and iron chelation. As
discussed in “Congenital anemias” and “Acquired anemias,” the
exact indication for iron chelation and the cost/benefit is much less
well established for patients with sickle cell disease (SCD),
myelodysplasia (MDS), and other refractory anemias.
We first highlight the available techniques used for assessing
iron status. We then review the efficacy, side effects, and how we
monitor treatment with the 3 currently licensed iron chelators
deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX)
alone or in combination. We then describe how we commence iron
chelation in adults and children with TM and transfusional iron
overload in conditions other than TM. The overall management of
TM has already been superbly reviewed in this series of How I
Treat,2 and recent excellent reviews of iron chelation therapy have
been published.3,4
Assessment of iron overload
Calculation of iron intake recording the number of units of blood
transfused is cost-effective and precise and can predict the total
iron that will accumulate in the body.
Serum ferritin
Serum ferritin measurement may be the only available method of
assessing iron burden in developing countries. It is useful for close
and frequent patient monitoring to indicate changes in iron burden.
More accurate measurements of iron stores (see next section) are
performed at less frequent intervals. Although serum ferritin has
been used for deciding when to start chelation therapy, it is now
known to be an inaccurate indicator of cardiac iron or of total body
iron burden. Serum ferritin also fluctuates in response to inflamma-
tion, abnormal liver function, and ascorbate deficiency. Despite
these reservations, there is an association, albeit weak, between the
level of serum ferritin and prognosis in TM.8-12
LIC
Liver iron concentration (LIC) accurately predicts total body iron
stores.13 When possible, it should be measured annually in patients
undergoing regular transfusion therapy. Normal LIC values are up
to 1.8 mg Fe/g dry weight, with levels of up to 7 mg/g dry weight
seen in carriers of genetic hemochromatosis without apparent
adverse effects. Several studies have linked very high LIC
( 15 mg/g dry weight) to worsening prognosis,10,14 liver fibrosis
progression,15 and liver function abnormalities.16 It is likely that
very high liver iron concentrations are associated with high plasma
non-transferrin bound iron (NTBI) because the liver is the main
organ for removing free iron from plasma. NTBI is damaging to the
organs that are also affected by iron deposition.
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Liver biopsy provides a direct measurement of LIC, being
quantitative, specific, and sensitive. Biopsy is an invasive proce-
dure, but in experienced hands it has a low complication rate.15
Inadequate sample size ( 1 mg/g dry weight or  4 mg wet
weight or  2.5 cm core length) or uneven distribution of iron,
particularly in the presence of cirrhosis, may give misleading
results.17 LIC can also be measured accurately by superconducting
quantum interference device. However, only 4 such machines are
available worldwide: they are expensive to purchase and maintain
and require dedicated trained staff. The results correlate well with
chemical estimation of LIC unless fibrosis is present.
MRI is more widely available, and it offers noninvasive
estimation of LIC. MRI scanners generate images of organs in
which the signal seen depends on iron concentration. Iron causes
the organ to darken more rapidly (Figure 1). T2* is the time needed
for the organ to lose approximately two-thirds of its signal and is
measured in milliseconds (ms). T2* shortens as iron concentration
increases. Its reciprocal, 1000/T2*, is known as R2* and is
measured in units of inverse seconds (S1).
MRI scanners can also measure T2 and R2 rather than T2* and
R2*, although technically this is slower and less straight forward.
The results of R2* and R2 for liver iron are similar.18 The technique
demonstrates an average sensitivity of  85% and specificity of
 92% up to an LIC of 15 mg/g dry weight and has been registered
in the European Union and the United States. For calibration, the
MRI machine must use a Phantom supplied by the company,
whereas the data acquired are sent via internet for analysis by the
dedicated FerriScan ISO 13285 accredited analysis facility (pay-
ment per scan analyzed). It can be applied with little training, at any
center with an up-to-date MRI machine. T2* MRI for liver iron
quantification is also widely used. Liver T2* calibration using a
clinically relevant MRI sequence has been published.18 T2*
measurement of LIC is reproducible between centers using a
clinical-grade MRI sequence.19 We prefer the T2* technique to T2
as it offers measurement of both cardiac and hepatic iron overload
at the same time (see next section). T2 and R2 for measuring
cardiac iron are less robust but widely used.
Cardiac iron
Estimation of myocardial iron using T2* MRI requires expertise
in its use and standardization. Good correlation between differ-
ent centers and machines has been shown,19 and the technique
has been recently validated as a true measure of cardiac iron,
correlating with chemical measurement on postmortem cardiac
biopsies.20 A shortening of myocardial T2* to  20 ms (imply-
ing increased myocardial iron above normal) is associated with
an increased likelihood of decreased left ventricular ejection
fraction (LVEF), whereas patients with T2* values  20 ms
have a very low likelihood of decreased LVEF.4 T2* values of
10-20 ms indicate a 10% chance of decreased LVEF; 8-10 ms
an 18% chance; 6 ms a 38% chance; and T2* values of 4 ms a
70% chance of decreased LVEF.7
Cardiac T2* therefore identifies those patients at risk of a fall in
LVEF whose chelation treatment should be intensified.5,12,21,22
Improved survival in patients with TM in the United Kingdom has
been attributed to the introduction of cardiac MRI T2* monitoring
with intensification of chelation if indicated as well as the
availability of the oral iron chelator DFP.23
Cardiac T2* does not correlate with serum ferritin concentra-
tion or liver T2* in patients receiving chelation therapy in a
cross-sectional analysis, although longitudinal studies may imply a
significant relationship.4-6 The discrepancy between cardiac iron
and LIC in many TM patients may be partly the result of the
differences in response to DFO therapy, which removes liver iron
more effectively than cardiac iron.24,25 However, even in the
absence of DFO therapy, TM patients may develop a cardiac T2*
 20 ms with LIC concentrations in the range of 1.2-9.0 mg/g dry
weight.26 Thus, cardiac MRI T2* measurement is needed in all
TM patients irrespective of their LIC or serum ferritin level. We
recommend that patients undergo cardiac MRI T2* measurement at
least yearly if they have abnormal values ( 20 ms) or more
frequently if with diagnosed heart disease; and once every 2 years
in those with values  20 ms and normal cardiac function. All
patients should have cardiac T2* measured if cardiac symptoms
develop.
Other measurements
Other tests of iron status cannot be recommended for regular
monitoring of iron overload or response to chelation therapy.
Measurement of NTBI is carried out only in a few research
Figure 1. Cardiovascular magnetic resonance T2* im-
ages showing the heart and liver from 3 different
patients at the same echo time (10.68 ms). (A) Normal
appearance with a bright myocardial and liver signal indicat-
ing that there is no significant cardiac or hepatic iron loading
(myocardial T2* 29 ms, liver T2* 22 ms). (B) Dark myocar-
dial signal indicating severe myocardial siderosis (heart
T2* 6.2 ms) but no liver iron (liver T2* 18 ms). *The spleen
also has high signal, suggesting that there is no significant
splenic iron loading. (C) Normal myocardial signal (heart
T2* 24 ms) but dark liver consistent with severe hepatic iron
overload (liver T2* 1.8 ms). Images courtesy of Dr J. P.
Carpenter (The Royal Brompton Hospital, London, United
Kingdom).
Table 1. Refractory anemias for which blood transfusions and iron
chelation may be needed
Congenital Acquired
TM Aplastic anemia
Thalassemia intermedia Red cell aplasia
Aplastic anemia (Fanconi) Myelodysplasia
Blackfan-Diamond anemia Chronic myelofibrosis
Sideroblastic anemia Paroxysmal nocturnal hemoglobinuria
Sickle cell anemia
Rarely in some cases of
congenital hemolytic anemia
(eg, pyruvate kinase,
glucose-6-phosphate
dehydrogenase deficiency)
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laboratories. Urine iron excretion after a single dose of a chelator
gives some measure of total iron stores in the case of DFP but not
for DFX or DFO where iron excretion is totally or partly by the
fecal route. Measurement of the degree of saturation of the plasma
iron binding capacity gives a rough idea of iron burden but is
affected by recent iron chelation therapy or inflammation. Values
 100%, however, suggest inadequate chelation and the need for
cardiac and liver iron determination.
Available chelators
DFO. DFO is the drug for which there is the longest experience in
treating transfusional iron overload (Table 2). It is usually self-
infused on at least 4 days a week over 8-12 hours. The usual dose is
40 mg/kg body weight, but higher doses up to 60 mg/kg have been
used in patients with high body iron stores. Even higher doses have
caused pulmonary and neurotoxicity and should be avoided.
Vitamin C (maximum 200 mg daily) may be given to correct
deficiency and to enhance iron excretion. Some units give intrave-
nous DFO (from a separate bag) with blood transfusion (eg, 1 g of
DFO for each unit of blood), but we do not recommend this in
children or in adults unless noncompliant and inadequately chelated.
The drug has transformed life expectancy for many patients
with TM and other refractory anemias. It has also reduced
endocrine and hepatic complications. Many patients with TM are
not satisfactorily chelated by it, however, and then may develop a
fatal cardiomyopathy. The reasons for these “failures” of DFO
therapy include cost of the drug, pump and tubing, poor compli-
ance,8 allergy, toxicity, local problems at the site of the infusions,
lack of 24-hour binding of NTBI,27 and Yersinia infection (not a
complication of the oral chelators). Even among patients appar-
ently complying with DFO infusions at least 5 times a week and
with serum ferritin levels 1000 g/L, some may develop cardiac
iron overload and failure.28 Approximately 20% of patients receiv-
ing DFO alone in the United Kingdom, Italy, and Cyprus have
cardiac T2* levels 10 ms.29
Safety monitoring. This has been the subject of several
excellent reviews and is only briefly discussed here.3,30,31 The main
side effects occur with high doses of the drug in patients,
particularly children, with low iron stores. These consist of damage
to the retina (night blindness, visual field loss, retinal pigmentation,
and changes on electrical tests) and high tone sensory neural
hearing loss. Growth and bone defects may also occur in children,
with rickets-like bone lesions, metaphyseal changes, and spinal
damage with loss of sitting height. A therapeutic index can be
calculated as follows: mean daily dose (mg/kg)/current serum
ferritin (g/L). If this is  0.025 at all times, these side effects of
DFO do not occur.32
Regular checks are needed for visual or auditory defects, in
children every 6 months and in adults annually. In children, checks
of growth, particularly sitting height compared with total height,
detect early spinal growth defects.
DFP (L1, 1,2 dimethyl, 3 hydroxy, pyrid-4-one, Ferriprox).
This bidentate iron chelator is rapidly absorbed with a peak blood
level about 45 minutes after ingestion. It is cleared rapidly from
plasma with 85% conversion in the liver to a glucuronide deriva-
tive. Differences in the speed of this conversion partly accounts for
Table 2. Comparison of DFO, DFP, and DFX
DFO (DFO) DFP (DFP) DFX (DFX)
Molecular weight 560 139 373
Chelator: iron 1:1 (hexandentate) 3:1 (bidentate) 2:1 (tridentate)
Route of administration Subcutaneous or intravenous Oral tablets or liquid Oral suspension
Iron excretion Urine, fecal Urine Fecal
Plasma half-life 20 min 1-3 h 8-16 h
Usual dose 40 mg/kg/d 75-100 mg/kg/d 20-40 mg/kg/d
Licensed Licensed for treatment of chronic
iron overload resulting from
transfusion-dependent anemia
In Europe, North America, and Asia: for
treatment of iron overload in TM where
DFO is contraindicated or inadequate
In the United States, licensed for treatment
of transfusional iron overload in patients
2 years or older. In Europe, approved for
treatment of transfusional iron overload in
TM, 6 years and older and when DFO is
contraindicated and inadequate, in
patients with other anemias, patients
2-5 years old and in nontransfusion-
dependent thalassemia
Cardiac iron removal Compliance problem; not
effective in all compliant patients;
continuous infusion more
effective
Most effective of the 3 chelators; used
with continuous DFO in cardiac failure
Reduces LIC and improves liver pathology;
reduces cardiac iron in 3-year study
Annual cost (54 kg body weight) 40 mg/kg/5 d  £4788* 75 mg/kg/d  £4505 20 mg/kg/d  £13 245
(United Kingdom NHS) 100 mg/kg/d  £6007 30 mg/kg/d  £19 865
Not applicable at the same rate in
all countries
40 mg/kg/d  £26 490
Main side effects Local reactions, auditory, retina,
allergy, bone abnormalities,
Yersinia infection
Gastrointestinal, neutropenia/
agranulocytosis, arthralgia, liver
enzyme rise, zinc deficiency†
Gastrointestinal, rash, renal, liver†
Advantages 36 years of experience Best for cardiac iron removal Once-daily administration
Disadvantages Mode of administration, lack of
compliance
Weekly blood count monitoring in
first year
Cost
Modified from Kwiatkowski4 with permission.
*Add cost of treating, needles pump.
†See also Table 3.
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a variation in efficacy between patients.33 It is usually given 3 times
daily to achieve maximum iron chelation. The usual starting dose is
75 mg/kg per day but, provided it is well tolerated, doses up to
100 mg/kg per day can be given to enhance iron excretion.34,35
Patient compliance is excellent compared with DFO.33
DFP has the lowest molecular weight of the 3 chelators and
penetrates cells to chelate iron from intracellular compartments,
such as lysosomes and mitochondria.36 DFP has emerged as
superior to DFO at reducing cardiac iron levels. Comparison of
359 Italian patients attending 7 centers between the years
1995-2003, treated with DFO alone or for the 157 switched to DFP
showed a clear superiority of DFP. In Italy, whereas no cardiac
deaths and no new cardiac events (arrhythmias or cardiac failure
needing drug therapy) occurred in a DFP group, 10 cardiac deaths
and 42 nonfatal cardiac events occurred in a DFO group.37 Four
retrospective studies in which cardiac iron in TM patients was
assessed by T2* MRI suggested that DFP was more effective than
DFO at removing cardiac iron. The patients receiving DFP had
higher LVEFs than those receiving DFO, although for liver iron,
the 2 drugs appeared equally effective.38-41
Prospective randomized trials have confirmed the superiority
of DFP alone compared with DFO at usual therapeutic doses,
at removing cardiac iron, improving left ventricular function,
and preventing death.42,43 This was shown initially for patients
with normal cardiac function and moderate cardiac siderosis
(T2* 8-20 ms).42 In a subsequent large observational study, DFP
improved all degrees of cardiac iron burden, including those
with T2*  8 ms.43 In this study, DFP also seemed superior to
DFX at lowering cardiac iron, although nonprospective limited
data were included.
Safety monitoring. The established side effects of deferiprone
were described within 2 years of the first clinical trials33 and their
incidence determined in large clinical trials43-45 (Table 3). The most
frequent are gastrointestinal, such as nausea, vomiting, and abdomi-
nal pain. A new liquid formulation has been reported to give fewer
gastrointestinal adverse reactions.46
The most serious side effect of DFP is agranulocytosis, a
neutrophil count of  0.5  109/L in 2 consecutive blood tests. It
occurs in  1% of patients, most frequently in the first year of
treatment, but it has been described in the second year or rarely,
later. It is reversible, but some deaths have occurred. The median
duration of agranulocytosis is 9 days (range, 3-85 days).
Agranulocytosis has appeared to be most frequent in patients
with the Blackfan-Diamond anemia.47,48 The mechanism is unclear.
G-CSF may be given. It does not shorten the period of agranulocy-
tosis but speeds recovery once this has begun. Rechallenge with the
drug should be avoided; and because of the risk of agranulocytosis,
patients receiving DFP should be warned to report immediately any
fever or sore throat. We recommend blood tests every week for the
first year of therapy and at least every 2 weeks thereafter.
Lesser degrees of neutropenia, neutrophils 0.5-1.5  109/L,
occur more frequently (Table 3). This is more common in patients
with intact spleens and reversible on stopping the drug. Rechal-
lenge is worthwhile because neutropenia may not recur or the
neutrophils may settle at a safe, albeit subnormal, level.
An arthropathy affecting mainly large joints, especially the
knees, occurs in a proportion of patients. The arthropathy usually
resolves after stopping the drug, and often the drug can be
successfully reintroduced at the same or a lower dose. Patients may
also develop pains in the muscles, which resolve without interrupt-
ing therapy.
Transient rises in liver enzymes occur in  7% of patients, but
these usually fall to normal without stopping the drug. In 1% of
patients, the rises persist and the drug is then discontinued. The
drug does not cause liver fibrosis.33
Zinc deficiency was first reported to occur in diabetic TM
patients receiving DFP, and this was associated with increased
urine zinc excretion.44 In large trials, there has been a small overall
fall in plasma zinc levels but few below the normal range.44 The
deficiency is easily detected by measuring serum zinc levels and
corrected with zinc supplements without diminishing iron chelation
efficacy.
Combined therapy: DFO and DFP
DFP given on each day of the week, and subcutaneous DFO
infusions given on some or all of these days was introduced in
1998 for patients inadequately chelated by maximum tolerated
doses of DFP.34 The effect of the combined drugs on iron excretion
has been found on the basis of urine iron excretion and iron balance
studies to be additive or even synergistic.34,50 This has been
explained as a shuttle mechanism with DFP entering cells and
removing iron, which is then passed on to DFO for excretion in
urine or feces51 (Figure 2). The DFP may reenter cells and extract
more iron. In addition, recent studies show that DFP is capable of
rapidly accessing NTBI fractions in plasma and transferring this
iron to DFO.52 Shuttling of iron from DFP to DFO also applies to
iron removed from transferrin.53
Combination protocols have differed widely with doses of DFP
ranging from 50 to 100 mg/kg and DFO doses from 20 to 60 mg/kg
given in addition from 1 to 7 days each week.54 For patients in
cardiac failure, DFP is given daily with DFO continuously
(Table 4).
Combined chelation can be intensified or reduced by changing
the dose of either drug or by varying the number of days each
week DFO is infused. Patients comply better with self-administered
DFO when this is only needed on 1 or 2 days each week. In
addition, the dose of both drugs may be adjusted sufficiently low to
avoid side effects of either drug but to still give effective chelation.
This has enabled the successful use of combined therapy in
children in India.55
Combined therapy with DFO and DFP has been found effective
at improving cardiac iron assessed by T2* MRI, LVEF and
endothelial function.54,56,57 In Cyprus, where combination therapy
with DFP and DFO was introduced for all patients at high risk
of heart failure, there was a significant fall in mortality.58 In Italy,
a multicenter prospective randomized trial over 7 years in 265 pa-
tients found no deaths occurred in patients receiving DFP alone or
in combination with DFO, whereas 10 deaths occurred in those
receiving DFO alone.59 Lai et al confirmed the superiority of
combined therapy over DFO alone in treating established iron-
induced cardiac disease.60
In patients who tolerate combined therapy over several years, it
is possible to reduce total body iron burden in TM to normal,
assessed by serum ferritin and T2* measurement of cardiac and
liver iron and to improve endocrine function.61 Improvements in
glucose metabolism and gonadal function in both sexes have been
achieved.61 This contrasts with single-agent chelator therapy for
which there are no reports of significant reversal of endocrine
damage. Side effects from the combined therapy have been the
same as with either drug alone. There has been no increase in the
incidence of agranulocytosis, and no new toxicity.
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Alternating therapy: DFP and DFO
The regimen of giving the 2 drugs on different days each week has
been termed alternating or sequential therapy. It is aimed at
improving compliance with both drugs and at giving some form of
chelation every day. In the largest prospective study59,62 in the
sequential arm, the patients received DFP 75 mg/kg on 4 days a
week and DFO 50 mg/kg on 3 days. Follow-up was a minimum of
5 years. One death from cardiac arrhythmia occurred. In view of
the efficacy of and usual compliance with combined DFO and DFP
therapy, we have not found it necessary to resort to alternating
therapy.
DFX. DFX is the most recently introduced iron chelator,
except in North America where DFX was licensed before DFP. In
contrast to DFP, iron excretion is via the fecal route (Table 2). As
DFX has a long half-life in plasma, levels are maintained within the
therapeutic range over a 24-hour period (Table 2). It can therefore
provide 24-hour chelation cover and binding of NTBI with only
once daily administration.
To date, DFX clinical experience extends over 9 years, with
 8000 patients investigated across several transfusion-dependent
anemias. In a randomized phase 3 trial in 586 patients with TM, a
DFX dose of 30 mg/kg per day significantly reduced LIC and
serum ferritin. The efficacy of DFX doses of 20 or 30 mg/kg per
day was comparable with that of 40-60 mg/kg per day of DFO
infused 5 days/wk.63 DFX was also shown to be effective at
reducing iron burden in patients who were heavily iron overloaded
Table 3. DFP- and DFX-related adverse effects and their management
Adverse events
Incidence in
core trials, % Monitoring and management
DFP-related
Gastrointestinal (nausea, vomiting,
and abdominal pain)
33 in first y Mild: continue drug or reduce dose. If severe, discontinue drug temporarily and restart at lower dose.
Try liquid formation. 5% of patients discontinue drug permanently.
Neutropenia (neutrophils
 1.5  109/L)
8.5 Monitor blood count weekly for first year, fortnightly in second and subsequent years. Stop drugs for a
few weeks. Rechallenge and continue drug if neutrophils at safe level of  1.5  109/L.
Agranulocytosis (neutrophils
 0.5  109/L)
1 Stop drug, treat with intravenous antibiotics if febrile. Give G-CSF if neutropenia prolonged
and/or febrile.
Rise in transaminases 7 Continue to monitor without stopping drug. Enzymes usually fall to normal. If persistently raised
 2 times ULN (  1% of patients), discontinue drug.
Arthropathy 3.9-41 Related to degree of iron overload in some series. Stop drug temporarily and restart at lower dose.
 2% of patients stop drug permanently because of arthropathy.
Zinc deficiency Rare: mainly in
diabetes
Give zinc supplements.
DFX-related*
Gastrointestinal
Diarrhea 8.8 Patients should take an antidiarrheal for up to 2 days and keep hydrated. DFX could be taken in the
evening rather than the morning. Products, such as Lactaid (if the patient is lactose intolerant) or
probiotics (acidophilus or lactobacillus), could be added to the diet.
Abdominal pain 5.0 Patients should sip water or other clear fluids, and avoid solid food for the first few hours. Avoid
narcotic pain medications and nonsteroidal anti-inflammatory drugs. DFX could be taken in the
evening rather than the morning.
Nausea/vomiting 14.3 Patients should drink small, steady amounts of clear liquids, such as electrolyte solutions, and
keep hydrated.
Skin rash
Mild to moderate 4.3 Likely to resolve spontaneously. DFX should be continued without dose adjustment.
Severe 0.4 DFX should be interrupted and reintroduced at a lower dose. Patients should take low-dose oral
steroids for a short period of time.
Renal changes 36 Serum creatinine levels should be assessed in duplicate before therapy, then monthly. If patients
have additional renal risk factors, serum creatinine levels should be monitored weekly for the
first month or after modification of DFX therapy, then monthly.
 33% above pretreatment
values at 2 consecutive visits
(not attributed to other
causes)
11 DFX dose should be reduced by 10 mg/kg.
Progressive increases beyond the
ULN
0 DFX should be interrupted, then reinitiated at a lower dose followed by gradual dose escalation if the
clinical benefit outweighs the potential risks.
Pediatrics, 33% above
pretreatment values and
above the age-appropriate
ULN at 2 consecutive visits
11 DFX dose should be reduced by 10 mg/kg.
Changes in liver function (elevation
in transaminases)
2 Liver function should be monitored monthly. After any severe or persistent elevations in serum
transaminase levels, dose modifications should be considered. DFX therapy can be cautiously
reintroduced once transaminase levels return to baseline.
Auditory and ocular alterations  1 Auditory and ophthalmic function should be tested before initiating therapy and annually thereafter.
ULN indicates upper limits of normal.
*Data from Vichinsky.81
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at baseline64 and who eventually required dose escalation to
 30 mg/kg per day.65 DFX has demonstrated long-term (5 year)
dose-dependent efficacy in both adult and pediatric patients66 and
was recently shown to be associated with improvement in iron-
related hepatic pathology.67 DFX has been associated with greater
patient satisfaction and adherence to therapy, and increased time
available for normal activities compared with DFO.68
DFX has been found effective in removing iron from the heart
in patients with baseline T2* 5-10 ms (severe) and T2* 10-20 ms
(mild to moderate iron loading).69-71 Among 71 patients with
various degrees of cardiac siderosis, cardiac T2*significantly
improved from a mean of 12.0-17.1 ms over a 3-year period.72
LVEF in these patients was normal at the start of the study and did
not change. Another study (US04) showed that monotherapy with
DFX was effective in chelating cardiac iron in patients with mild to
moderate hepatic iron stores but was borderline significant for
removal of cardiac iron in patients with severe hepatic iron
burden.73
A small number of patients have been treated with twice-daily
DFX apparently increasing tolerability and efficacy.74 Until the
results of larger studies have been reported, this interesting
approach cannot be recommended.
Safety monitoring. In general, DFX has shown a favorable
safety profile at high doses ( 30 mg/kg per day), and in patients
achieving serum ferritin levels 1000 g/L65,75-81 (Table 3). As for
DFP, side effects do not appear more frequent or severe at low iron
levels, but we recommend reduction in dose or discontinuation of
both drugs when the serum ferritin is 500 g/L.
The most common adverse events attributed to DFX therapy are
gastrointestinal disturbances and skin rash (Table 3). Diarrhea is
more common in the elderly. Mild, nonprogressive increases in
serum creatinine and liver enzyme levels have also be noted.
Recommendations for their monitoring and management are sum-
marized in Table 3. A boxed warning was added to the United
States DFX prescribing information, although this amendment has
not been adopted by the European Health Authority or applied
globally. The warning indicates that DFX may cause renal and
hepatic impairment, including failure, and gastrointestinal hemor-
rhage. In some reported cases, these reactions were fatal. However,
these reactions were observed in patients with advanced age,
high-risk MDS, and those with underlying renal or hepatic
impairment or low platelet counts. DFX is contraindicated in
patients with renal and hepatic failure.81
Combined or alternating therapy: DFX and DFO
As yet, there are no reports of large studies, and we do not
recommend these protocols, except in a clinical trial setting. In one
study published by abstract only, 15 TM patients with LIC
 15 mg/kg or with lower LIC concentration, but evidence of
iron-related organ damage was treated with DFX 20-30 mg/kg
daily combined with DFO 35-50 mg/kg subcutaneously on 3-7 days
each week.82 Liver iron improved significantly after a mean of
29 weeks. No excessive toxicity was seen. As both DFO and DFX
primarily remove liver iron, their combined effects may not be
additive as they may compete for the same iron pool. This was so in
a gerbil model.83
Sequential therapy of these chelators has been suggested as an
attractive option. In a small study of 7 iron-overloaded TM
patients, patients received 20-30 mg/kg per day of oral DFX for
4 consecutive days, then a subcutaneous infusion of 20-40 mg/kg
per day of DFO for 8-12 hours on the next 3 consecutive days.84 All
of the patients showed a decrease in serum ferritin without any side
effects. This protocol warrants further evaluation in larger patient
numbers, but currently we do not recommend it.
Combined therapy: DFP and DFX
Three studies of combined chelation with the 2 oral chelators DFP
and DFX have been reported. In the largest, 16 patients were
treated with DFP 75-100 mg/kg per day in 3 divided doses together
with DFX 20-25 mg/kg each day.85 There was a fall in total body
iron measured by serum ferritin, liver iron and cardiac iron
measured by T2* MRI. Improvements occurred in LVEF, gonadal
function, and glucose metabolism. Compliance was excellent and
quality of life improved for the patients who stopped using DFO
infusions. Side effects were no different from those when the drugs
are used as monotherapy. In 2 other reports, a total of 4 patients also
showed improvement in cardiac iron, cardiac function with excel-
lent compliance, and no unexpected side effects.86,87 Further long
term studies in a larger number of patients are needed before this
combined, attractive (to patients), oral chelation strategy can be
recommended.
Figure 2. The “shuttle” mechanism by which DFP
given orally binds iron from transferrin (TF), NTBI,
and intracellular compartments and transfers some
of this iron to DFO. The free DFP is then available to
bind more iron. Some DFO also enters cells to bind iron
directly.
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FBS0701
FBS0701 is a novel, orally available member of the desazadesferri-
thiocin class of siderophore-related tridentate chelators currently in
clinical development. In preclinical studies, FBS0701 bound
Fe(III) with very high affinity and selectivity and demonstrated a
 4-fold higher no-observable-adverse-effect level compared with
DFX, suggesting a favorable clinical safety profile, especially with
respect to gastrointestinal and renal toxicity.88 Multidose safety and
pharmacokinetic studies in iron-overloaded patients established the
acute safety of FBS0701 and the feasibility of once-a-day dosing,89
and a phase 2 study has now been reported confirming these
observations.90
General principles of iron chelation therapy
Initiating therapy
Before initiation or change of iron chelation therapy, TM patients
should be evaluated for the rate of transfusional iron loading (Table
4) and previous chelation. Serum ferritin, LIC, and cardiac T2*
MRI and cardiac, hepatic, renal, and endocrine (thyroid, parathy-
roid, pancreatic, gonadal, and pituitary) function also need to be
tested.2,91,92 Potential for pregnancy and the growth and develop-
ment in children are also assessed.2 The overall prognosis in the
chronic anemias other than TM must be assessed. If this is poor (eg,
in high-risk myelodysplasia patients), it may not be necessary to
institute iron chelation. The same clinical and laboratory tests
should be used for initiating and monitoring efficacy of chelation
therapy, as for TM.
For patients already satisfactorily chelated on one or other
chelator, no change in chelation is needed. Patients in North
America and the European Community starting chelation as
adolescents or adults have to choose initially between DFO or
DFX. After the advantages and disadvantages of the 2 drugs have
been explained, most opt for DFX. In some countries (eg, Turkey),
DFP is also approved as first-line treatment. It is licensed in the
European Community for the treatment of iron overload, in patients
with thalassaemia major when deferoxamine therapy is contraindi-
cated or inadequate (Table 2). In the United States, the indication is
for the treatment of patients with transfusional iron overload
because of thalassaemia syndromes when current chelation therapy
is inadequate. Efficacy at tolerable doses, comorbidities, drug side
effects, compliance often related to patient preferences, and special
patient populations and clinical trials require favoring the use of
one regimen over another. These considerations also determine on
which chelation regimen the patient is continued. In North America
where DFP was only licensed in 2011, DFX is the most widely
used, but in the United Kingdom and other parts of the world (eg,
India and the Far East) where DFP has been licensed for 10 years or
more, DFP alone or in combination with DFO is used by a
substantial proportion of patients.90
In TM, we recommend initiating chelation therapy as soon as
transfusions have caused enough iron excess to potentially cause
tissue damage. Usually in TM, this is at the age of 2 years or older.
Current practice is to start after first 10-20 transfusions, when the
serum ferritin level is  1000 g/L, or when LIC is  7 mg Fe/g
dry weight. Dosing should be tailored according to transfusional
iron intake to achieve levels below these thresholds and a cardiac
T2*  20 ms. A discussion with the parents will be needed
explaining the advantages and disadvantages of the different drugs.
Maintenance therapy
Maintenance therapy is adjusted to prevent tissue damage because
of iron overload.36,91,92 A LIC 15 mg/g dry weight, serum ferritin
 2500 g/L or cardiac T2* MRI  20 ms indicate inadequate
chelation. If cardiac iron overload is present (T2*  20 ms),
cardiac iron removal becomes the primary goal of therapy (Table
4). As discussed in the sections dealing with the individual
drugs, not all patients are satisfactorily chelated on DFO, DFP,
or DFX alone. In many, the dose or frequency of DFO infusions
must be revised or the patient switched to another chelator or
switched to combined therapy (eg, of DFO with DFP). The iron
intake from blood can also be reduced in TM patients by
splenectomy if blood requirements are unusually high ( 200-
220 mL packed red cells/kg/year).
Monitoring for side effects
This is carried out at appropriate intervals relevant to the chelator
or chelators being used (Table 3). Depending on the severity of side
effects, reduction of dose, switching to another chelator or use of
combined therapy may be needed. In general, side effects with
DFO are most frequent at low iron burdens, whereas for DFX and
DFP side effects appear to be equivalent at different levels of iron
burden.
Monitoring efficacy
Cardiac siderosis. Intensification of chelation is needed for all
patients with a cardiac T2* 15 ms, whatever the serum ferritin or
LIC. Fall in LVEF because of cardiac siderosis or cardiac failure or
arrhythmia is best treated by the combination of DFO intrave-
nously (or subcutaneously) at doses of 40-60 mg/kg per day and
deferiprone orally 75 mg/kg per day.
Liver iron. This should be monitored by MRI. Levels 15 mg/g
dry weight indicate that commencement or intensification of
chelation is needed. Chelation should be tailored as far as possible
to achieve a LIC 7 mg/g/dry weight.
Special populations
Pediatric patients. Chelation strategies in the adult TM population
(see previous section) can be applied in children with special
considerations as follows. Initially in children a dose of DFO
20-30 mg/kg per day is used to avoid toxicity with a maximum
dose of 40 mg/kg in children whose growth has ceased.2,91 Close
monitoring of growth and bone development is needed if DFO is
started at age 3 years. In the United States (FDA), DFX can also
be used to initiate treatment in children as young as 2 years,
commencing at a dose of 20 mg/kg. In Europe (European Medi-
cines Evaluation Agency), DFX is only approved as a second-line
drug for children younger than 6 years. Compliance in young
children may be better to DFO infusions than to oral DFX, but most
parents choose DFX. DFX has also had no reported adverse effect
on children’s growth or on adolescent sexual development in both
patients with TM and SCD.66,81 However, monitoring for renal
toxicity in children is particularly important.94 A recent study of
DFP therapy found that, with the newly introduced liquid formula-
tion, the efficacy and safety profile in 100 children 1-10 years of
age was similar to that in older children or adults.46 In developing
countries, cost and compliance considerations may make DFP a
first choice for children.
Pregnancy. DFO is the only chelating drug that can be used in
pregnancy. It should be interrupted during the first trimester and
can be used in the second and third trimesters. A continuous
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intravenous infusion of DFO (50 mg/kg over 24 hours) can be
given before a planned pregnancy.91 DFP and DFX should be
stopped in pregnancy and during breast feeding. Sexually active
patients receiving DFX or DFP should use contraception.91
Congenital anemias
NTDT. Chelation in this disease has been discussed at length in a
special supplement.95 Nontransfusion-dependent thalassemia
(NTDT) describes patients with genetic disorders of hemoglobin
synthesis who are not sufficiently severe to warrant regular blood
transfusions but are more severely anemic than patients with - or

-thalassemia trait. Many different genotypes underlie NTDT,
-thalassemia intermedia, hemoglobin E/ thalassemia, hemoglo-
bin H, and hemoglobin E/ thalassemia being the most common.
The patients become progressively iron loaded with increasing
age mainly through increased iron absorption. In some patients,
transfusions often given at times of infections, during pregnancy or
to avoid bone complications, contribute to iron loading. Direct
assessment of LIC by biopsy or by MRI is recommended because
serum ferritin underestimates iron load in this patient population.96
Chelation is usually started with DFO but switched to one or other
oral chelator in those unable or unwilling to comply with DFO.97 In
some studies on E/-thalassemia, iron chelation with DFP has
resulted in an improvement in erythropoiesis and hemoglobin
levels.98 Clear guidelines are not available, but we use an LIC
 7 mg/g dry weight as an indicator to start iron removal.99
Preliminary data show that DFX is safe and removes iron in TI
patients.99,100 A large 1-year randomized, double blind, placebo-
controlled phase 2 prospective study on 166 NTDT patients
reported DFX to be both safe and efficacious.101 We do not
recommend venesections to reduce iron burden because these may
aggravate bone abnormalities by increasing anemia.
Blackfan-Diamond anemia. The indications for commencing
iron chelation therapy in Blackfan-Diamond anemia are similar to
those in TM. The first report of agranulocytosis with DFP was in an
adult patient with Blackfan-Diamond anemia,47 and the drug
should be avoided in this condition.48 There have been no
unexpected side effects in chelating DBA patients with DFX, and it
was effective at lowering LIC and serum ferritin, although less so
than in myelodysplasia.102 We recommend to try DFX in patients
inadequately chelated on DFO or with hypersensitivity to it.
Aplastic anemia. The British Society for Hematology Guide-
lines recommended DFO as first-line chelation therapy for both
congenital or acquired aplastic anemia.103 Particular problems may
arise because of infections or bleeding at the site of the injection.
We recommend DFX as second-line chelator and reserve DFP/
DFO for patients with a cardiomyopathy or a T2*  10 ms. A
recent subgroup analysis of 116 patients treated in the EPIC trial
with DFX for 1 year found significant reduction in serum ferritin in
both chelation naive and previously treated patients. Serum creati-
nine rose in 25% of the patients, especially in those receiving
cyclosporine.78 There were no drug-related cytopenias. A separate
study showed that DFX was equally effective as assessed by serum
ferritin and labile plasma iron in production or hemolytic anemias.101
Congenital sideroblastic anemia. The indication for chelation
and drugs to be used are similar to those in TM.
SCD. Blood transfusions have been used in SCD for patients at
risk of cerebrovascular accidents or with frequent life-threatening
crises. An increasing range of indications have now been identified
so that many patients with SCD have received multiple transfu-
sions by adulthood.104
All national guidelines recommend iron chelation in chronically
transfused patients with SCD, mainly to avoid liver damage. This is
supported by an 11.3% incidence of cirrhosis because of raised
total iron burden in an analysis of 141 adult SCD patients over a
25-year review.105
Assessment of SCD-specific populations has demonstrated that
elevated iron levels are associated with an increased frequency of
acute events, hospitalization, and death. Prospective trials are
needed to determine whether the increased iron levels are simply an
indicator of the more severely affected patients or increase
susceptibility to these other complications. Some studies have
shown that patients with SCD with high serum ferritin levels and
with a similar number of transfusions to those in TM had normal
cardiac T2* values5,106,107 and less endocrine damage.108
The indications for iron chelation therapy in patients with SCD
are, however, similar to those as outlined for adults with TM (Table
4). DFO remains the most widely used drug, but compliance with it
is particularly poor in SCD patients. A recent study on long-term
safety and efficacy of DFX for up to 5 years showed a clinically
acceptable safety profile, including maintenance of normal renal
function with appropriate DFX dosing, and iron burden was
substantially reduced.77 Serial measurement of the glomerular
filtration rate and of serum creatinine is indicated during DFX
safety monitoring.81,94 Oral therapy with DFP may be preferred if
renal damage is present. A recent review of 14 trials found that,
among 502 patients, treatment with DFO alone (subcutaneously or
intravenously), DFP alone, DFX alone, or combined treatment with
DFO and DFP had been used. Only 2 randomized trials had been
reported. The authors concluded that the use of chelation in SCD
has been based on little efficacy or safety evidence and the
cost:benefit ratio had not been fully explored.109 Further prospec-
tive studies are clearly needed.
Acquired anemias
Aplastic anemia has already been discussed. Iron-mediated organ
damage may occur in multiply transfused, low-risk MDS patients
with several reports highlighting that mortality rate is greater in
heavily iron-overloaded MDS patients developing hepatic and
cardiac dysfunction.110-112 These and other studies have shown an
association between high iron levels and increased mortality in
MDS treated conventionally or after stem cell transplantation.113,114
It is difficult to be certain, however, how far the iron loading in all
these studies directly reduces survival or is a marker for those
patients with a poor prognosis because of the length and severity of
the MDS.111,115-117 An early T2* MRI study in 11 patients showed
that cardiac function and MRI T2* tended to remain normal for a
long latent period in MDS patients, even with hepatic iron
loading.118 A more recent study in 43 multiply transfused MDS
patients found 16.8% with a cardiac T2* 20 ms.119
Leitch has critically reviewed published data on the benefits and
risks of iron chelation therapy in MDS.117 Some studies, often
retrospective, have shown improved survival or reduced transforma-
tion to acute myeloid leukemia.117,120 A recent matched-pair
analysis of 188 iron-loaded MDS patients in which 94 patients
received long-term chelation with DFO or DFX and 94 did not,
found median survival significantly longer in the chelated group.121
These data support the hypothesis that iron overload plays a role in
decreasing survival in multiply transfused low-risk MDS. Emerg-
ing data also suggest that iron chelation may be beneficial for
overall survival in multiply transfused high-risk MDS and in those
selected for stem cell transplantation.
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Several studies have shown improvement in white cell and
platelets in MDS treated with DFO or DFX.122,123 An improved
hemoglobin level, in some cases obviating the need for transfusions
has also been described in MDS patients treated with DFO or
DFX.117,122,124-126 This effect may be at least partly because of
removal of excess iron from the iron- and oxygen-dependent prolyl
hydroxylase in the renal oxygen sensing system for erythropoietin
production.127,128 Reduction of oxidative stress, which may inhibit
hematopoiesis, has also been suggested.123 Prospective randomized
trials currently in progress will help to determine which patients
with MDS will benefit from chelation therapy whether for leuke-
mic transformation, overall survival, for hepatic or endocrine
complications, for transfusion requirements, and for other hemato-
logic parameters.
We recommend that transfusion-dependent MDS patients with
an otherwise good prognosis (life expectancy  1 year) in whom
chelation therapy is considered necessary should generally be
managed as outlined for TM (Table 4). Various national and
international guidelines have been published recommending star-
ing chelation in low and intermediate-1 risk MDS (defined by an
international prognostic score) after 20-30 units of blood have been
transfused and with serum ferritin levels  1000 g/L in some,
 2500 g/L in other guidelines. Liver and cardiac iron concentra-
tions are also useful in deciding whether or not to start chelation
therapy.
Choice of chelation for patients with MDS, chronic myelofibro-
sis, red cell aplasia, paroxysmal hemoglobinuria, and other severe
acquired anemias may not be easy. DFO and DFX are licensed for
first-line therapy. DFO may be difficult to administer because of
excessive bruising or infection at the infusion site because of
cytopenias. On the other hand, extra caution should be used in
treating elderly MDS patients or elderly patients with myelofibrosis
or other refractory anemias with DFX because of their greater
frequency of decreased hepatic, renal, or cardiac function, not
related to iron overload, and of concomitant disease or other drug
therapy.115-117 DFP is not advisable because of the risk of agranulo-
cytosis, but the incidence of this in MDS is probably no higher than
in TM.33 The relative costs of the drugs may influence choice in
many countries (Table 2).
Future prospects
The outlook for patients with TM and other transfusion-dependent
anemias has improved substantially with the availability of 3 iron-
chelating drugs and the use of T2* MRI to detect cardiac siderosis
before cardiac symptoms develop. Combined therapy with DFO
and DFP has proved particularly effective at treating a previously
fatal iron-induced cardiomyopathy. In the United Kingdom, infec-
tion rather than iron-induced cardiomyopathy is now the main
cause of mortality in TM.23 It seems likely that patient preference
and compliance will result in the increased use of the oral chelators
and corresponding reduced use of subcutaneous DFO. Randomized
trials of oral chelators against DFO may become more difficult to
perform because of patient preference. This will be particularly so
if a third orally active iron chelator becomes clinically available.
With each drug alone, however, a proportion of patients, perhaps
20%, will be inadequately chelated because of lack of efficacy or
because the drug dosage has to be reduced or stopped because of
side effects. Switching chelators and combination therapy of the
oral chelators is likely to increase in use so a randomized trial of the
2 oral chelators DFP and DFX in combination against alternative
chelation regimens is urgently needed.
For developing countries, the oral chelators are particularly
attractive if the costs can be kept low. Clinical trials are taking
place of DFP, which alone of the 3 chelators can cross the
blood-brain barrier,129 in conditions, such as Friedrich ataxia and
Parkinson disease, with excess iron deposits in the brain. Treatment
of diseases, where iron overload is localized to a single organ, will
need to be the subject of a future How I Treat review.
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